The global oncology market is projected to reach USD 279.98 billion in 2026, growing to USD 748.17 billion by 2035 at a CAGR of 11.54%.5
Key trends shaping 2026 include new IO backbones (PD-(L)1×VEGF, checkpoint-plus bispecifics, early solid-tumor cell therapy), ADC 2.0 platforms, radiopharmaceuticals advancing to earlier treatment lines, evolving diagnostics with ctDNA-MRD and MCED, AI integration across oncology processes, and China-to-global sourcing models.1
Experts forecast advances in early detection, prevention, personalized treatment, immunotherapies for hard-to-treat tumors, AI for discovery and diagnosis, and efforts to reduce care disparities in 2026.2
Antibody-drug conjugates (ADCs) are expected to see dynamic growth and move into curative settings, with high likelihood of continued expansion in 2026.47
North America holds about 43% market share, driven by advanced healthcare and R&D; Asia-Pacific is the fastest-growing region.58
Health equity and closing disparities in cancer care by race, income, and geography are taking center stage.3
Sources:
1. https://bluematterconsulting.com/insights/whitepaper/oncology-market-outlook-2026/
2. https://www.aacr.org/blog/2026/01/08/experts-forecast-cancer-research-and-treatment-advances-in-2026/
3. https://www.evernorth.com/articles/oncology-trends-2026
4. https://oncodaily.com/voices/cancer-care-2
5. https://www.towardshealthcare.com/insights/oncology-market-sizing
7. https://cromospharma.com/esmo-2025-insights-from-the-floor-what-will-really-change-oncology-in-2026/
8. https://www.intelmarketresearch.com/cancer-treatment-drugs-market-21693